**Name of Journal: *World Journal of Methodology***

**ESPS Manuscript NO: 21982**

**Manuscript Type: REVIEW**

**Immunodiagnosis of human hydatid disease: Where do we stand?**

Sarkari B *et al*. Immunodiagnosis of hydatid cyst

**Bahador** **Sarkari, Zahra Rezaei**

**Bahador Sarkari**, Basic Sciences in Infectious Diseases Research Center, Shiraz University of Medical Sciences, Shiraz 71345-1735, Iran

**Zahra Rezaei**, Department of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz 71345-1735, Iran

**Author contributions:** Sarkari B performed the literature search, wrote the first draft of the manuscript, edited and approved the final version; Rezaei Z performed the literature and approved the final version of the manuscript.

**Conflict-of-interest** **statement:** The authors declare that there are no conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Bahador Sarkari, PhD, Professor** of Immunoparasitology, Basic Sciences in Infectious Diseases Research Center, Shiraz University of Medical Sciences, Shiraz 71345-1735, Iran. sarkarib@sums.ac.ir

**Telephone:** +98-71-32305291

**Fax:** +98-71-32305291

**Received:** August 4, 2015

**Peer-review started:** August 6, 2015

**First decision:** September 22, 2015

**Revised:** October 26, 2015

**Accepted:** November 13, 2015

**Article in press:**

**Published online:**

**Abstract**

Cystic echinococcosis (CE) is a zoonotic parasitic infection caused by the larval stage of *Echinococcus granulosus*. Diagnosis of CE mainly relies on a combination of serological testing along with imaging approaches. A variety of serological methods, mainly based on hydatid cyst fluid (HCF), antigen B (AgB) and antigen 5 (Ag5), have been developed and used for immunodiagnosis of CE, yet their performances are not satisfactory. Although utilizing of recombinant or synthetic antigens, improved the performance of serological tests, it has not applicably overcome the problem of low sensitivity and cross reactivity, seen in the diagnosis of CE. Performances of immunodiagnostic tests based on AgB subunits are promising. The 8 kDa subunit of AgB is the most studied antigen in native, synthetic or recombinant form for diagnosis of CE. From the 5 subunits of AgB, antigen B8/1 and B8/2 provided the highest diagnostic sensitivity and specificity. Moreover, detecting of specific antibodies of IgG subclasses has improved the efficacy of immunodiagnostic tests. Among the IgG subclasses, both IgG2 and IgG4 are considered as good markers for diagnosis and IgG4 as a suitable marker for follow up of the patients. In this review an overview of immunodiagnostic methods, related antigens and their performances in the diagnosis of CE are given. The paper highlights pitfall and challenges in the serological diagnosis of CE. Moreover, limitation of currently available immunodiagnostic tests and the most recent development in the designing and application of serological assays for diagnosis of CE in human are addressed.

**Key words:** Immunodiagnosis; Cystic echinococcosis; Hydatid cyst

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Cystic echinococcosis (hydatid cyst) is one of the most important parasitic diseases, causing tremendous morbidity and mortality for the human patients. Diagnosis of CE mainly relies on ultrasound images of the cyst along with serological testing. So far, there is no highly specific and sensitive immunodiagnostic test for diagnosis of CE and performances of the currently available tests are not satisfactory. Different antigenic sources including hydatid cyst fluid, antigen B and 5, excretory-secretory antigens of larval stage or adult worm have widely been used for development of serological assays for diagnosis of CE. Utilizing of antigen B subunits in immunodiagnostic tests and detection of IgG subclasses, as a good marker, opened a promising perspective in diagnosis of this debilitating disease.

Sarkari B, Rezaei Z. Immunodiagnosis of human hydatid disease: Where do we stand? *World J Methodol* 2015; In press

**INTRODUCTION**

Cystic echinococcosis (CE), known as hydatid cyst or hydatid disease, is a zoonotic parasitic infection caused by the larval stage of Echinococcus granulosus. Dogs and other canids harbor the adults tape worm and herbivores acts as intermediate host and become infected through ingestion of parasite’s eggs. Human acquire the infection by accidental ingestion of E.granulosus eggs.

CE with its significant economic and medical impact constitutes an important public health problem in many developing countries[1-3]. An estimated 1.2 million people worldwide are affected by CE and the disease accounts for annual estimate of 3.6 million DALYs (disability adjusted life years) through the world[4]. Early and proper diagnosis of CE can provide appropriate management and suitable treatment of the disease[5].

Diagnosis of CE is mainly confirmed through a combination of relevant history, serological testing, along with imaging approaches. A variety of serological methods have been developed and used for immunodiagnosis of CE in recent years, including indirect hemagglutination (IHA), immunoblotting, enzyme-linked immunosorbent assay (ELISA), indirect fluorescent-antibody (IFA), latex agglutination test, and Immunochromatography test (ICT)[1,6-11]. For the development of these assays different antigens from adult worm, protoscolices, worm eggs or hydatid cyst fluid have been defined, purified and evaluated in the aforementioned serological tests.

Diagnosis of CE has drastically improved during the last two decades. Progress in methods for antigen purification, cloning expression and purification of E. granulosus recombinant antigens, and defining and synthesis of immunodominant peptides contributed to this development. Nevertheless, immunodiagnosis of CE is still problematic. Commercially available serological tests show unsatisfactory performance. The lack of standardization of immunodiagnostic assays and also antigen preparation contribute to discrepancy in results reported in different laboratories. Cyst size, stage and location as well as patients characteristics may be accounted for the discrepancy of the same test performance in different clinical diagnostic laboratories.

Hence, serological assays still have a complementary role to imaging in the diagnosis of CE. Low sensitivity (up to 30% of false negativity) and also low specificity (up to 25% of false positivity) make serological results difficult to interpret[12-17].

***Pitfalls and challenges in the diagnosis of CE***

In spite of the development of a variety of immunodiagnostic test, following diagnostic pitfalls and challenges still exist in the diagnosis of CE.

Available immunodiagnostic tests give a relatively high rate of false-negativity. False negative results in immunodiagnostic tests for CE may be seen in patients with small cysts, intact cysts, cysts in extrahepatic locations, heavily calcified cysts (*e.g.,* non-viable), or cyst in privilege sites (brain or eye). Akbulut *et al* reported that 15 out of 40 patients with pancreatic echinococcosis, found in the literature have had negative serological testing for CE[18]. Among 65 CE patients in Germany, false negative serological results were reported in 18% by IHA and in 15% by ELISA[19]. In a study by Akcam *et al*[20] more than 20% of patients with extra-hepatic cysts were reported to be negative by indirect hemagglutination (IHA) test. Using WB, 10 cases of IHA-negative were found to be positive[20]. In a study by Wuestenberg *et al*[21], CE was confirmed in 9 cases of IHA-negative by clinical findings and imaging (US). Cardiac hydatid cyst, with 54 x 45mm size, was serologically negative in Canpolat *et al*[22] report. Karakasli *et al* reported a case of large spinal-para spinal hydatid cyst with negative ELISA and WB testing[23]. They suggested that chemical and neuro-radiological findings should be considered in such cases. Review of 100 case of pulmonary hydatidosis by Zapatero *et al*[24] revealed that a positive serological test have been present with ruptured cyst (positive IHA in all of ruptured cyst) while the test detected only 80% of patients with unruptured cysts. Serological test for CE have been negative In HIV-positive cases[25].

Currently available tests give rather high rate of false-positive reaction in patient infected with other parasites (notably cestodes) or even in healthy subjects. False positive results are related to cross reactant antibodies.

Differentiation of past (cured or calcified cyst) from present (active or progressive) hydatid infection is difficult by existing antibody detection assays. Antibody titer may remain for years, even after surgical removal of the cyst or proper drug treatment[26,27]. Therefore a positive serological test may not necessarily imply the presence of active cyst or even the reactivation of CE.

Hydatid cysts in unusual locations may complicate its diagnosis. Congenital, choledochal and pancreatic pseudocysts along with lipoma, ovarian intra-abdominal cystadenoma and intra-hepatic haematoma may be misdiagnosed as hydatid cyst by ultrasonography/ computerized tomography (US/CT)[13]. In all of these conditions an appropriate serological test would be quite helpful with negative results.

Performance of serological tests varies in different pathological stage of CE according to WHO classification[28].

A single defined molecule may not be sufficient for diagnosis of CE. Recent immunoproteome analysis of HCF, in different stages of cyst (based on WHO classification), revealed that specific immunodominant epitopes changes from[29]. This indicates that more than one defined immunodominant antigen may be needed to diagnosis CE in different status of the cyst.

***Antigenic sources for immunodiagnosis of CE***

Antigenic sources which have widely been used for immunodiagnosis of CE are HCF, component of HCF, ES of protoscolices or adult worm, and also extract of adult worm or larval stage. Antigen for immunodiagnosis of CE has been comprehensively reviewed by Carmena *et al*[12]. The main antigens for diagnosis of CE and their performance in diagnosis of CE are discussed below.

**HCF:** HCF is the most common antigenic source which has been used for diagnosis of CE. HCF is a mixture of host (albumin, globulins) and parasite components[30-32]. Sensitivities of serological tests based on HCF are high but their specificities are far from satisfactory (30%-90%)[8, 10,12,28,31,33-35]. Many of available commercial kits are using HCF in ELISA system for diagnosis of CE. Table 1 summarizes the performance of HCF in diagnosis of CE in different serological assays.

Using HCF as a source of antigen, Sedaghat *et al*[35] evaluated the performance of a simple dot ELISA and CCIEP for diagnosis of human hydatidosis and found a sensitivity and specificity of 100% and 89.1% for Dot-ELISA and 80% and 62% for CCIEP. Dot ELISA had a better performance in comparison with CCIEP. Using HCF, EL-Shazly *et al*[8] reported a sensitivity of 96.7% and specificity of 97.5% for ELISA and 86.7% and 95% for IHA. Al-Sherbiny *et al*[6] applied the camel HCF in a dipstick assay and reported a high diagnostic sensitivity (100%) and specificity (91.4%).

CCIEP is a relatively sensitive, but not specific method for diagnosis of CE. In a retrospective study conducted by Sadjjadi *et al*[15] hospital records of 1227 surgically proven CE cases were examined and found that only 62% of cases had a CCIEP positive test in comparison with 96.3% of positive findings by US and pathology.

**Ag5:** Ag5 is one of the most immunogenic and abundant part of HCF. It composed of 57 and 67 kDa components and dissociate into 38 and 22-24 kDa subunits under reducing conditions[36]. Ag5, after AgB, is one of the most studied antigens in the serodiagnosis of CE. Numerous studies pointed out that Ag5 has a high rate of cross-reactivity with sera of healthy controls or other non-CE patients[12,17,37]. Its performances in native, recombinant or synthetic forms have not been satisfactory due to either low sensitivity (50-54), or specificity because of cross reactivity with sera of the patients with other cestoda, trematoda or even nematode. In an Ag5-base ELISA, Khabiri *et al*[38] reported that IgE and IgG4 are the most important antibodies, with low cross reactivity with sera of healthy control and non-CE cases.

Contrary to these reports, a recent study by Pagnozzi *et al*[39] demonstrated that highly enriched Ag5, by chromatographic method, attained highly specific and unambiguous results, in western blotting and ELISA system in diagnosis of CE. The authors indicated that low performance of this antigen in previous studies is related to non-properly purified antigen which have been used and considered that highly purified Ag5 is a promising antigen in diagnosis of CE. Having said that the low number of sera tested in their study does not allow drawing a decisive conclusion. Table 2 shows the performance of Ag5 in diagnosis of CE in different serological assays.

**AgB:** AgB is a thermostable polymeric lipoprotein of 120-160 kDa, composed of 8 kDa subunits which dissociates into 8/12, 16 and 24 kDa subunits, under reducing condition in SDS-PAGE[36]. AgB is considered as the main antigen of HCF with high specificity and sensitivity in serological diagnosis of CE[9,10,31,40-42].

AgB is highly immunogenic, a feature that makes this antigen a suitable candidate for immunodiagnosis of CE. The smallest subunit, 8 kDa, considered as the most appropriate antigen in diagnosis of CE. Not surprisingly, the 8 kDa subunit of AgB is the most studied antigen in native, synthetic or recombinant form for diagnosis of CE. Sarkari *et al*[42] obtained diagnostic sensitivity and specificity of 100% and 80% when AgB was evaluated in an immunoblotting system. In their study from 40 sera of hydatidosis patients, 32 cases (80%) detected the 8 kDa subunit, 29 cases (72.5%) recognized the 16 kDa component and 29 cases (72.5%) detected the 24 kDa subunit of antigen B. In continuation of their study, when the AgB was used in an ELISA system, sensitivity of the system was determined to be 92.5% and the specificity was found to be 97.3%[10].

Recombinant AgB are not doing much better in diagnosis of CE when compared with native homologues antigens. The performance of rAgB subunits for diagnosis of CE was evaluated by Jiang *et al*[40] where they reported performance order of AgB1 > AgB4 > AgB2 > AgB5 > AgB3. It was found that in some cases antibodies against subunits of AgB was not produced. In another study, Jiang *et al*[43] reported that AgB1 has higher diagnostic sensitivity in comparison with AgB2 and AgB4. However, in Virginio *et al*[44] study, antigen B8/2 provided the highest diagnostic sensitivity (93.1%) and specificity (99.5%) in ELISA system. In Leggatt *et al*[45] study, a sensitivity of 90.9% was reported for the 12 kDa subunit of AgB (corresponding to the smallest subunit of AgB) in a blotting system. More than 5% (5.5%) of cysticercosis patients reacted with this subunit.

The 12 kDa subunit of AgB, was cloned and expressed by Abdi *et al*[46]. The antigen was comparatively evaluated for diagnosis of CE, with native AgB and HCF. The sensitivity and specificity of rAgB, in ELISA system was similar to HCF (96% and 97%), and lower than native AgB (98.6% and 100%).

A recombinant antigen of B8/1 (rAgB), showed a high sensitivity (94.6%) and specificity (93.9%) for diagnosis of CE, using serum samples from Iran, China and Japan, in comparison with HCF, native AgB, prepared from sheep HCF, either from Iran of Japan[31].

Mamuti *et al*[41] cloned and produced recombinants of EmAgB8/1 from *E. multilucolaris* and EgAgB/1 from *E. granulosus* and evaluated their antigenic reactivity in western blotting and ELISA in comparison with that of counterpart, an 8 kDa subunit of AgB. WB showed reactivity with 81.3% of sera from CE patients and 40.6% of sera from alveolar echinococcosis (AE) patients, while EgAgB8/1 showed reactivity with 86% of CE and 42% of AE patients. Both EmAgB/1 and EgAgB/1 showed similar reactivity with 37.8% of serum from AE and 88% of sera from CE patients.

A synthetic P176 peptide related to N-terminal extreme of AgB/1 subunit yielded a sensitivity and specificity of 78.69 and 96.88 for pulmonary hydatid cyst[47].

Application of antigen B in a dot immunogold filtration assay increased the test specificity (98.3%) but in turn decreased the sensitivity (77.9%) of the assay, compared to native antigen[48].

Source of antigen B is an important factor which affects the performance of the test for diagnosis of CE. In agreement with this, Rahimi *et al*[49] showed that AgB isolated from human and sheep liver cyst have the best performance in diagnosis of CE when compared with those antigen obtained from liver or lungs cyst of goat, cattle or camel.

Combination of antigen B and antigen 5 may increase the sensitivity of the test as current used in a commercially available test. The commercially available Rapid Immunochromatography test VIRapid® HYDATIDOSIS test (Vircell, Spain) using antigen 5/B was evaluated by Tamer *et al* for diagnosis of CE where they reported a sensitivity of 96.8% and specificity of 87.5%. In their study, the antigen cross reacted with sera from taeniasis and leishmaniasis patients and also a few (4%) of healthy controls[50].

Nature and quality of antigen B, isolated from HCF, may be variable based on the host species, cyst location, cyst status and also parasite strain. This is one of the reasons that different laboratories attain different results using AgB in serodiagnosis of CE. In view of this point, discrepancies in results of serodiagnosis of CE, using antigen B might be related to, method of antigen preparation, variation in host and strain of parasite, differences in antigen B, site of the cyst, clinical status and type of the cyst. Table 3 shows the performances of antigen B in diagnosis of CE in different serological assays.

**Protoscolices antigens:** Native metacestode-derived antigens show substantial (mainly more than 90%) sensitivities in diagnosis of CE[51]. However cross-reactivity with other parasitic diseases (fascioliasis, schistosomiasis, amebiasis, taeniasis, cysticercosis and filariasis) is the main drawback of using such antigens for serodiagnosis of CE. The best performance for serological tests of ELISA, IHA and IFA, was achieved for ELISA (87.5% sensitivity and 100% specificity), using metacestode antigen[52].

**Detection of IgG subclasses:** Detecting of specific antibodies of IgG subclasses may improve the diagnostic performance of immunodiagnostic tests. Xu *et al*[53] examined the seroreactivity of 42 IgG negative (total IgG) with IgM, IgE, IgA, and IgG subclasses and found that 32 cases were positive with either one or combined of two of other antibodies. The best seropositivity (42.95%) was reported with either IgG1 alone or a combination of IgG1 + IgA + IgM. IgG subclasses is usually linked to the status of cyst development. Findings of Daeki *et al*[54] demonstrated that IgG antibody response is associated with the growth and development of cyst, while IgG1,2 and 3 responses are predominantly related to involutive phase in CE cysts. Patients with relapsing disease have a high level of IgG4 titer.

Lawn *et al*[55] demonstrated that concentration of CE-specific IgG subclasses (IgG1-4), are much correlated with disease activity than total IgG. Among the IgG subclasses, IgG2 provided the best correlation with clinical outcome. In a lateral fellow dipstick test, a sensitivity of 95% and specificity of 100% was reported for detection of IgG4, in comparison with IgG dipstick with 87.5% specificity[56]. Detection of antibodies mainly IgG subclasses (IgG1, 4) in urine of CE patients provide a similar result in comparison to serum sample in Chirag study[57].

***Antigen detection for immunodiagnosis of CE***

Antigen detection has been used for diagnosis of a few of parasitic diseases with satisfactory results[58-61]. Antigen detection might be useful for detection of current infection and also post treatment follow up of CE patients. However results with detection of hydatid cyst antigen for detection of CE are far from satisfaction[7,11,62-64].

Antigen detection in CE is much less sensitive than antibody detection and the later remains the most commonly used approach for diagnosis of this disease. Antigen can be detected in sera of 35%-85% of CE patients depends on the status and location of the cyst[7,16,63]. In some cases of CE circulating antigen has been detected in sera of patients who had not shown anti-hydatid antibodies in their serum. Sawarna *et al*[11] reported a sensitivity of only 53.33% and specificity of 96.66% in a Dot-ELISA system for detection of hydatid cyst antigen in urine samples. Lower sensitivity (29.68) was obtained when CCIEP was used for detection of hydatid urinary antigen[62].

Using coagglutination test, a sensitivity of 47.5% was achieved for detection of hydatid antigen in urine[63]. Several interfering factors have been proposed to explain the poor performance of antigen-detection assays in diagnosis of CE. Formation of immune complexes and low availability of free antigen, sequestration of antigen due to cyst layers, especially in intact cyst, and presence of interfering component in serum or urine, as demonstrated in other studies[58]. Cysts in privileged sites (*e.g.,* eye and brain) do not release enough antigens to be detected by serological assays.

Location of the cyst is an important issue in diagnosis of CE as one study pointed out that CE antigen can be detected in 46% of patients with liver cyst but not in any of patients with lung hydatid cyst[16]. In an attempt to develop an antigen detection assay for diagnosis of CE, Sadjjadi *et al*[16] evaluated an ELISA system for detection of circulation antigens in serum of CE patients. In their study, antigen was detected in only 9 out of 35 (25.7%) of cases. Table 4 summarizes the performance of antigen detection assays in diagnosis of CE.

**Post treatment follow up:** CE patients need to be followed up after treatment, to make sure about the risk of recurrence. Anti-CE antibodies may persist for several years after treatment[55]. Although antigen detection might be a useful approach in post-treatment follow-up, however its low sensitivity hampered its use for patients’ follow-up. Different serological assays have been used for monitoring of surgically or chemically treated CE patients[26,64-66].

In a recent cohort study, CE patients were followed for a mean of 6 years and the level and isotypes of antibodies were evaluated before and after surgical or anti-helminthic drugs treatment. Results demonstrated that IgE, IgG1 and IgG4 are the most important antibodies for serological diagnosis of active CE. During post-operation, IgM, IgE, IgG1, IgG2 and IgG4 were the best correlative with disease activities[67]. Reiterova *et al*[68] reported that antibodies to AgB was not detectable three months after treatment but antibodies to HCF were remained detectable.

It has been reported that subclasses of IgG have different performance in diagnosis of primary in comparison to relapse cases of CE. One study suggested IgG2 as a good marker for primary infection and total IgG for detection of relapse cases[69].

Recombinant P29 protein of *E. granulosus* was synthesized by Ben Nouir *et al*[64] and evaluated for post-surgical follow-up of CE patients, in an ELISA and WB systems. Results indicated that, using P29-ELISA, all of initially seropositive cases of CE seroconverted to negative within three years after treatments, while HCF-ELISA remained positive in 90% of cases. Western blotting, using P29, remained positive in only 10% of cases after 3 years while HCF-WB remained positive in more than 25% of cases after 3 years of follow-up. However the performance of P29 in initial diagnosis of CE has not been satisfactory.

In another study by this group, somatic protoscolex antigens of *E. granulosus* have been assessed for follow-up of surgically treated CE patients and found that only 29% of treated patients reaching seronegativity after 5 years of follow up. The conventional HCF-ELISA becoming negative in 15% of cases at the end of the follow up period[65].

A double 27 and 28 kDa antigen, in WB, was also reported as useful antigen for the follow up of CE patients. However such bands were only detectable in 75% of the patients before treatment[65]. The prognostic value of AgB subunits was evaluated by Ben Nouir *et al*[64] in ELISA and WB systems. Patients were grouped into either cured or non-cured CE patient. Findings of the study showed that ELISA remained positive 4-5 years after treatment in 57.1% of cured and 100% of non-cured patients. Immunoblotting, based on AgB subunits (8 and 16 kDa), revealed 14.3% of seropositivity after 4 years, with no reactivity to the components after 5 years of follow up. Interestingly, WB remained positive in 100% of non-cured patients up to 5 years (end of follow-up period). Serum antibodies to a certain bands (24 and 39) of HCF in western blotting decreased in post-surgical monitoring of CE patients[70].

**CONCLUDING REMARKS AND PERSPECTIVES**

The performances of currently available immunodiagnostic test in diagnosis of CE are not satisfactory and the best serological test for diagnosis of CE is still the subject of debate. Over the time, particularly during the last two decades, several immunodiagnostic tests have been developed, mainly based on HCF, AgB and Ag5, yet their performance in diagnosis of human hydatidosis are unsatisfactory.

The most widely used antigens for serological diagnosis of CE are AgB and Ag5. Yet new antigens are being constantly evaluated and new serological assays are being increasing developed to improve the performance of serological diagnostic tests.

Utilizing of recombinant or synthetic antigen although improved the performance, but has not overcome the problem of low sensitivity or even cross reactivity with other antigen in diagnosis of CE and these problems still remained. Considerable variation in performance of serological test for diagnosis of CE between different laboratories is mainly related to lack of standardization of antigen preparation, inadequate sensitivities and specificity, and also strain of the parasite that antigens have been purified from its content.

Immunodiagnostic tests based or recombinant antigen has drawn the attention of many researchers and the outcomes of such studies are promising. These antigens, especially based on AgB subunits, showed not all the times, but in most cases, satisfactory performance in comparison to their homologues antigens.

New interesting perspective in the development of serological assays for diagnosis of CE might be derive from recent observation that IgG subclasses are good markers for diagnosis and also follow up of CE patients. Moreover, the evaluation of highly purified Ag5 for immunodiagnosis of CE seems to be a promising task ahead which must be undertaken in the future. And finally immunodiagnosis assays may well be improved through combining of several well-defined antigens, notably immunodominant antigen in different stages of the cyst development.

**ACKNOWLEDGMENTS**

Technical assistance of Reza Shahriari Rad is appreciated.

**REFERENCES**

1 **Sarkari B**, Sadjjadi SM, Beheshtian MM, Aghaee M, Sedaghat F. Human cystic echinococcosis in Yasuj District in Southwest of Iran: an epidemiological study of seroprevalence and surgical cases over a ten-year period. *Zoonoses Public Health* 2010; **57**: 146-150 [PMID: 19175567 DOI: 10.1111/j.1863-2378.2008.01200.x]

2 **Sadjjadi SM**. Present situation of echinococcosis in the Middle East and Arabic North Africa. *Parasitol Int* 2006; **55** Suppl: S197-S202 [PMID: 16337429 DOI: 10.1016/j.parint.2005.11.030]

3 **Eckert J**, Deplazes P. Biological, epidemiological, and clinical aspects of echinococcosis, a zoonosis of increasing concern. *Clin Microbiol Rev* 2004; **17**: 107-135 [PMID: 14726458]

4 **Budke CM**, Deplazes P, Torgerson PR. Global socioeconomic impact of cystic echinococcosis. *Emerg Infect Dis* 2006; **12**: 296-303 [PMID: 16494758 DOI: 10.3201/eid1202.050499]

5 **Zhang W**, Wen H, Li J, Lin R, McManus DP. Immunology and immunodiagnosis of cystic echinococcosis: an update. *Clin Dev Immunol* 2012; **2012**: 101895 [PMID: 22235225 DOI: 10.1155/2012/101895]

6 **Al-Sherbiny MM**, Farrag AA, Fayad MH, Makled MK, Tawfeek GM, Ali NM. Application and assessment of a dipstick assay in the diagnosis of hydatidosis and trichinosis. *Parasitol Res* 2004; **93**: 87-95 [PMID: 15103552]

7 **Devi CS**, Parija SC. A new serum hydatid antigen detection test for diagnosis of cystic echinococcosis. *Am J Trop Med Hyg* 2003; **69**: 525-528 [PMID: 14695090]

8 **El-Shazly AM**, Saad RM, Belal US, Sakr T, Zakae HA. Evaluation of ELISA and IHAT in serological diagnosis of proven cases of human hydatidosis. *J Egypt Soc Parasitol* 2010; **40**: 531-538 [PMID: 21246959]

9 **González-Sapienza G**, Lorenzo C, Nieto A. Improved immunodiagnosis of cystic hydatid disease by using a synthetic peptide with higher diagnostic value than that of its parent protein, Echinococcus granulosus antigen B. *J Clin Microbiol* 2000; **38**: 3979-3983 [PMID: 11060055]

10 **Sadjjadi SM**, Abidi H, Sarkari B, Izadpanah A, Kazemian S. Evaluation of enzyme linked immunosorbent assay, utilizing native antigen B for serodiagnosis of human hydatidosis. *Iran J Immunol* 2007; **4**: 167-172 [PMID: 17767016 DOI: IJIv4i3A5]

11 **Swarna SR**, Parija SC. Evaluation of Dot-ELISA and enzyme-linked immuno-electrotransfer blot assays for detection of a urinary hydatid antigen in the diagnosis of cystic echinococcosis. *Trop Parasitol* 2012; **2**: 38-44 [PMID: 23508649 DOI: 10.4103/2229-5070.97238]

12 **Carmena D**, Benito A, Eraso E. Antigens for the immunodiagnosis of Echinococcus granulosus infection: An update. *Acta Trop* 2006; **98**: 74-86 [PMID: 16527225 DOI: 10.1016/j.actatropica.2006.02.002]

13 **Hira PR**, Shweiki HM, Francis I. Cystic hydatid disease: pitfalls in diagnosis in the Middle East endemic area. *J Trop Med Hyg* 1993; **96**: 363-369 [PMID: 8254715]

14 **Liance M**, Janin V, Bresson-Hadni S, Vuitton DA, Houin R, Piarroux R. Immunodiagnosis of Echinococcus infections: confirmatory testing and species differentiation by a new commercial Western Blot. *J Clin Microbiol* 2000; **38**: 3718-3721 [PMID: 11015390]

15 **Sadjjadi SM**, Ardehali S, Noman-Pour B, Kumar V, Izadpanah A. Diagnosis of cystic echinococcosis: ultrasound imaging or countercurrent immunoelectrophoresis? *East Mediterr Health J* 2001; **7**: 907-911 [PMID: 15332731]

16 **Sadjjadi SM**, Sedaghat F, Hosseini SV, Sarkari B. Serum antigen and antibody detection in echinococcosis: application in serodiagnosis of human hydatidosis. *Korean J Parasitol* 2009; **47**: 153-157 [PMID: 19488422 DOI: 10.3347/kjp.2009.47.2.153]

17 **Siracusano A**, Bruschi F. Cystic echinococcosis: progress and limits in epidemiology and immunodiagnosis. *Parassitologia* 2006; **48**: 65-66 [PMID: 16881399]

18 **Akbulut S**, Yavuz R, Sogutcu N, Kaya B, Hatipoglu S, Senol A, Demircan F. Hydatid cyst of the pancreas: Report of an undiagnosed case of pancreatic hydatid cyst and brief literature review. *World J Gastrointest Surg* 2014; **6**: 190-200 [PMID: 25346801 DOI: 10.4240/wjgs.v6.i10.190]

19 **Orhun A**, Müller-Stöver I, Holtfreter MC, Dedelen H, Häussinger D, Richter J. [Epidemiological and clinical characteristics of patients with echinococcosis - management in an infectiological service in Germany]. *Dtsch Med Wochenschr* 2012; **137**: 1039-1044 [PMID: 22570097 DOI: 10.1055/s-0032-1304951]

20 **Akcam AT**, Ulku A, Koltas IS, Izol V, Bicer OS, Kilicbagir E, Sakman G, Poyrazoglu H, Erman T, Aridogan IA, Parsak CK, Inal M, Iskit S. Clinical characterization of unusual cystic echinococcosis in southern part of Turkey. *Ann Saudi Med* 2014; **34**: 508-516 [PMID: 25971825 DOI: 10.5144/0256-4947.2014.508]

21 **Wuestenberg J**, Gruener B, Oeztuerk S, Mason RA, Haenle MM, Graeter T, Akinli AS, Kern P, Kratzer W. Diagnostics in cystic echinococcosis: serology versus ultrasonography. *Turk J Gastroenterol* 2014; **25**: 398-404 [PMID: 25254522 DOI: 10.5152/tjg.2014.7112]

22 **Canpolat U**, Yorgun H, Sunman H, Aytemir K. Cardiac hydatid cyst mimicking left ventricular aneurysm and diagnosed by magnetic resonance imaging. *Turk Kardiyol Dern Ars* 2011; **39**: 47-51 [PMID: 21358231]

23 **Karakasli A**, Yilmaz M, Mucuoglu AO, Yurt A. A large primary dumbbell hydatid cyst causing neural foraminal widening of the thoracic spine: A case report and literature review. *Int J Surg Case Rep* 2015; **8**C: 55-58 [PMID: 25625491 DOI: 10.1016/j.ijscr.2014.12.036]

24 **Zapatero J**, Madrigal L, Lago J, Baschwitz B, Pérez E, Candelas J. Surgical treatment of thoracic hydatidosis. A review of 100 cases. *Eur J Cardiothorac Surg* 1989; **3**: 436-440 [PMID: 2635924]

25 **Coupland U**, Dobosz S, Zawadka K, Marczyńska M. Cystic echinococcosis in a child infected with HIV. *Ann Parasitol* 2012; **58**: 101-103 [PMID: 25165762]

26 **Nouir NB**, Nuñez S, Frei E, Gorcii M, Müller N, Gianinazzi C, Mekki M, Nouri A, Babba H, Gottstein B. Post-surgical follow-up (by ELISA and immunoblotting) of cured versus non-cured cystic echinococcosis in young patients. *Parasitology* 2008; **135**: 105-114 [PMID: 17767795 DOI: 10.1017/s0031182007003502]

27 **Piccoli L**, Tamarozzi F, Cattaneo F, Mariconti M, Filice C, Bruno A, Brunetti E. Long-term sonographic and serological follow-up of inactive echinococcal cysts of the liver: hints for a "watch-and-wait" approach. *PLoS Negl Trop Dis* 2014; **8**: e3057 [PMID: 25122222 DOI: 10.1371/journal.pntd.0003057]

28 **Mariconti M**, Bazzocchi C, Tamarozzi F, Meroni V, Genco F, Maserati R, Brunetti E. Immunoblotting with human native antigen shows stage-related sensitivity in the serodiagnosis of hepatic cystic echinococcosis. *Am J Trop Med Hyg* 2014; **90**: 75-79 [PMID: 24297816 DOI: 10.4269/ajtmh.13-0341]

29 **Ahn CS**, Han X, Bae YA, Ma X, Kim JT, Cai H, Yang HJ, Kang I, Wang H, Kong Y. Alteration of immunoproteome profile of Echinococcus granulosus hydatid fluid with progression of cystic echinococcosis. *Parasit Vectors* 2015; **8**: 10 [PMID: 25566682 DOI: 10.1186/s13071-014-0610-7]

30 **Haghpanah B**, Mosavat B, Ghayour Z, Oreizi F. Diagnostic value of hydatid cyst antigens using western blotting method. *Jundishapur J Microbiol* 2010; **3**: 175-185

31 **Mohammadzadeh T**, Sako Y, Sadjjadi SM, Sarkari B, Ito A. Comparison of the usefulness of hydatid cyst fluid, native antigen B and recombinant antigen B8/1 for serological diagnosis of cystic echinococcosis. *Trans R Soc Trop Med Hyg* 2012; **106**: 371-375 [PMID: 22472966 DOI: 10.1016/j.trstmh.2012.01.012]

32 **Tawfeek GM**, Elwakil HS, El-Hoseiny L, Thabet HS, Sarhan RM, Awad NS, Anwar WA. Comparative analysis of the diagnostic performance of crude sheep hydatid cyst fluid, purified antigen B and its subunit (12 Kda), assessed by ELISA, in the diagnosis of human cystic echinococcosis. *Parasitol Res* 2011; **108**: 371-376 [PMID: 20922427]

33 **Jin Y**, Anvarov K, Khajibaev A, Hong S, Hong ST. Serodiagnosis of echinococcosis by ELISA using cystic fluid from Uzbekistan sheep. *Korean J Parasitol* 2013; **51**: 313-317 [PMID: 23864742 DOI: 10.3347/kjp.2013.51.3.313]

34 **List C**, Qi W, Maag E, Gottstein B, Müller N, Felger I. Serodiagnosis of Echinococcus spp. infection: explorative selection of diagnostic antigens by peptide microarray. *PLoS Negl Trop Dis* 2010; **4**: e771 [PMID: 20689813 DOI: 10.1371/journal.pntd.0000771]

35 **Sedaghat F**, Sadjjadi SM, Hosseini SV, Kazemian S, Sarkari B. Evaluation of a simple Dot-ELISA in comparison with countercurrent immunoelectrophoresis for diagnosis of human hydatidosis. *Clin Lab* 2011; **57**: 201-205 [PMID: 21500727]

36 **Lightowlers MW**, Liu DY, Haralambous A, Rickard MD. Subunit composition and specificity of the major cyst fluid antigens of Echinococcus granulosus. *Mol Biochem Parasitol* 1989; **37**: 171-182 [PMID: 2481826]

37 **Di Felice G**, Pini C, Afferni C, Vicari G. Purification and partial characterization of the major antigen of Echinococcus granulosus (antigen 5) with monoclonal antibodies. *Mol Biochem Parasitol* 1986; **20**: 133-142 [PMID: 3092046]

38 **Khabiri AR**, Bagheri F, Assmar M, Siavashi MR. Analysis of specific IgE and IgG subclass antibodies for diagnosis of Echinococcus granulosus. *Parasite Immunol* 2006; **28**: 357-362 [PMID: 16879307]

39 **Pagnozzi D**, Biosa G, Addis MF, Mastrandrea S, Masala G, Uzzau S. An easy and efficient method for native and immunoreactive Echinococcus granulosus antigen 5 enrichment from hydatid cyst fluid. *PLoS One* 2014; **9**: e104962 [PMID: 25119821 DOI: 10.1371/journal.pone.0104962]

40 **Jiang L**, Zhang YG, Liu MX, Feng Z. Analysis on the reactivity of five subunits of antigen B family in serodiagnosis of echinococcosis. *Exp Parasitol* 2012; **131**: 85-91 [PMID: 22446351 DOI: 10.1016/j.exppara.2012.03.009]

41 **Mamuti W**, Yamasaki H, Sako Y, Nakao M, Xiao N, Nakaya K, Sato N, Vuitton DA, Piarroux R, Lightowlers MW, Craig PS, Ito A. Molecular cloning, expression, and serological evaluation of an 8-kilodalton subunit of antigen B from Echinococcus multilocularis. *J Clin Microbiol* 2004; **42**: 1082-1088 [PMID: 15004057]

42 **Sarkari B**, Sadjjadi S, Abidi H, Izadpanah A, Kazemian S, Rafati A. Application of western blotting using native antigen B for serodiagnosis of human cystic echinococcosis. *Iran J Parasitol* 2007; **2**: 7-12

43 **Jiang L**, Feng Z, Zhang YG, Wang ZY. [Serodiagnosis of the recombinant multi-epitope antigens from antigen B subunits of Echinococcus granulosus]. *Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi* 2013; **31**: 438-442 [PMID: 24818408]

44 **Virginio VG**, Hernández A, Rott MB, Monteiro KM, Zandonai AF, Nieto A, Zaha A, Ferreira HB. A set of recombinant antigens from Echinococcus granulosus with potential for use in the immunodiagnosis of human cystic hydatid disease. *Clin Exp Immunol* 2003; **132**: 309-315 [PMID: 12699422]

45 **Leggatt GR**, Yang W, McManus DP. Serological evaluation of the 12 kDa subunit of antigen B in Echinococcus granulosus cyst fluid by immunoblot analysis. *Trans R Soc Trop Med Hyg* 1992; **86**: 189-192 [PMID: 1440787]

46 **Abdi J**, Kazemi B, Mohebali M, Bandehpour M, Rahimi MT, Rokni MB. Gene cloning, expression and serological evaluation of the 12-kDa antigen-B subunit from Echinococcus granulosus. *Ann Trop Med Parasitol* 2010; **104**: 399-407 [PMID: 20819308 DOI: 10.1179/136485910X12743554760261]

47 **Santivañez SJ**, Arias P, Portocarrero M, Rodriguez S, Gonzalez AE, Gilman RH, Gavidia CM, Garcia HH. Serological diagnosis of lung cystic hydatid disease using the synthetic p176 peptide. *Clin Vaccine Immunol* 2012; **19**: 944-947 [PMID: 22518012 DOI: 10.1128/cvi.05540-11]

48 **Chen X**, Chen X, Lu X, Feng X, Wen H. The production and comparative evaluation of native and recombinant antigens for the fast serodiagnosis of cystic echinococcosis with dot immunogold filtration assay. *Parasite Immunol* 2015; **37**: 10-15 [PMID: 25313824 DOI: 10.1111/pim.12151]

49 **Rahimi H**, Sadjjadi S, Sarkari B. Performance of antigen B isolated from different hosts and cyst locations in diagnosis of cystic echinococcosis. *Iran J Parasitol* 2011; **6**: 12-19 [PMID: 22347269]

50 **Tamer GS**, Dündar D, Uzuner H, Baydemir C. Evaluation of immunochromatographic test for the detection of antibodies against Echinococcosis granulosus. *Med Sci Monit* 2015; **21**: 1219-1222 [PMID: 25921809 DOI: 10.12659/msm.893155]

51 **Schweiger A**, Grimm F, Tanner I, Müllhaupt B, Bertogg K, Müller N, Deplazes P. Serological diagnosis of echinococcosis: the diagnostic potential of native antigens. *Infection* 2012; **40**: 139-152 [PMID: 22076692 DOI: 10.1007/s15010-011-0205-6]

52 **Sari C**, Ertuğ S, Karadam SY, Ozgün H, Karaoğlu AO, Ertabaklar H. [The comparative evaluation of Enzyme Linked Immunosorbent Assay (ELISA), Indirect Hemagglutination Test (IHA) and Indirect Fluorescent Antibody Test (IFAT) in the diagnosis of cystic echinococcosis]. *Turkiye Parazitol Derg* 2009; **33**: 73-76 [PMID: 19367551]

53 **Xu MQ**, Zhu B, Xue HC, Li X, Guo XR, Zhang YH, Li H. [Reexamination of specific antibodies in sera of cystic echinococccosis patients with IgG negative seroresponse]. *Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi* 2002; **20**: 148-151 [PMID: 12567989]

54 **Daeki AO**, Craig PS, Shambesh MK. IgG-subclass antibody responses and the natural history of hepatic cystic echinococcosis in asymptomatic patients. *Ann Trop Med Parasitol* 2000; **94**: 319-328 [PMID: 10945041]

55 **Lawn SD**, Bligh J, Craig PS, Chiodini PL. Human cystic echinococcosis: evaluation of post-treatment serologic follow-up by IgG subclass antibody detection. *Am J Trop Med Hyg* 2004; **70**: 329-335 [PMID: 15031526]

56 **Khalilpour A**, Sadjjadi SM, Moghadam ZK, Yunus MH, Zakaria ND, Osman S, Noordin R. Lateral flow test using Echinococcus granulosus native antigen B and comparison of IgG and IgG4 dipsticks for detection of human cystic echinococcosis. *Am J Trop Med Hyg* 2014; **91**: 994-999 [PMID: 25200268 DOI: 10.4269/ajtmh.14-0170]

57 **Chirag S**, Fomda BA, Khan A, Malik AA, Lone GN, Khan BA, Zahoor D. Detection of hydatid-specific antibodies in the serum and urine for the diagnosis of cystic echinococcosis in patients from the Kashmir Valley, India. *J Helminthol* 2015; **89**: 232-237 [PMID: 24429044 DOI: 10.1017/s0022149x13000837]

58 **Sarkari B**, Chance M, Hommel M. Antigenuria in visceral leishmaniasis: detection and partial characterisation of a carbohydrate antigen. *Acta Trop* 2002; **82**: 339-348 [PMID: 12039673]

59 **Sarkari B**, Hatam GR, Mikaeili F, Sadeghi H, Ebrahimi S. A comparative study of antigen and antibody detection in visceral leishmaniasis using serum and urine-based ELISA. *Trop Biomed* 2008; **25**: 96-99 [PMID: 18948879]

60 **Ghatei MA**, Hatam GR, Hossini MH, Sarkari B. Performance of latex agglutination test (KAtex) in diagnosis of visceral leishmaniasis in Iran. *Iran J Immunol* 2009; **6**: 202-207 [PMID: 20054108 DOI: IJIv6i4A5]

61 **van Dam GJ**, de Dood CJ, Lewis M, Deelder AM, van Lieshout L, Tanke HJ, van Rooyen LH, Corstjens PL. A robust dry reagent lateral flow assay for diagnosis of active schistosomiasis by detection of Schistosoma circulating anodic antigen. *Exp Parasitol* 2013; **135**: 274-282 [PMID: 23850995 DOI: 10.1016/j.exppara.2013.06.017]

62 **Parija SC**. Urinary antigen detection for diagnosis of parasitic infections. *Parasitol Today* 1998; **14**: 5-6 [PMID: 17040680]

63 **Ravinder PT**, Parija SC, Rao KS. Urinary hydatid antigen detection by coagglutination, a cost-effective and rapid test for diagnosis of cystic echinococcosis in a rural or field setting. *J Clin Microbiol* 2000; **38**: 2972-2974 [PMID: 10921961]

64 **Ben Nouir N**, Gianinazzi C, Gorcii M, Müller N, Nouri A, Babba H, Gottstein B. Isolation and molecular characterization of recombinant Echinococcus granulosus P29 protein (recP29) and its assessment for the post-surgical serological follow-up of human cystic echinococcosis in young patients. *Trans R Soc Trop Med Hyg* 2009; **103**: 355-364 [PMID: 19027129 DOI: 10.1016/j.trstmh.2008.09.020]

65 **Ben Nouir N**, Nuñez S, Gianinazzi C, Gorcii M, Müller N, Nouri A, Babba H, Gottstein B. Assessment of Echinococcus granulosus somatic protoscolex antigens for serological follow-up of young patients surgically treated for cystic echinococcosis. *J Clin Microbiol* 2008; **46**: 1631-1640 [PMID: 18367566 DOI: 10.1128/jcm.01689-07]

66 **Ciobotaru MD**, Luca M, Cobzaru RG. Surgical management of pulmonary hydatidosis in children. *Rev Med Chir Soc Med Nat Iasi* 2014; **118**: 753-758 [PMID: 25341297]

67 **Tenguria RK**, Naik MI. Evaluation of human cystic echinococcosis before and after surgery and chemotherapy by demonstration of antibodies in serum. *Ann Parasitol* 2014; **60**: 297-303 [PMID: 25706429]

68 **Reiterová K**, Auer H, Altintaś N, Yolasigmaz A. Evaluation of purified antigen fraction in the immunodiagnosis of cystic echinococcosis. *Parasitol Res* 2014; **113**: 2861-2867 [PMID: 24828349 DOI: 10.1007/s00436-014-3947-0]

69 **Benabid M**, Galai Y, Nouira R, Bouchoucha S, Bouratbine A, Aoun K. Contribution of specific anti-hydatid IgG subclasses in the diagnosis of echinococcosis primary infection and relapses. *Clin Lab* 2013; **59**: 293-298 [PMID: 23724617]

70 **Kumar Tenguria R**, Naik MI, Fomda B. Application of Western Blotting for the Post-Treatment Monitoring of Human Cystic Echinococcosis. *Iran J Public Health* 2013; **42**: 826-832 [PMID: 26056636]

71 **Sbihi Y**, Rmiqui A, Rodriguez-Cabezas MN, Orduña A, Rodriguez-Torres A, Osuna A. Comparative sensitivity of six serological tests and diagnostic value of ELISA using purified antigen in hydatidosis. *J Clin Lab Anal* 2001; **15**: 14-18 [PMID: 11170228]

72 **Hernández-González A**, Muro A, Barrera I, Ramos G, Orduña A, Siles-Lucas M. Usefulness of four different Echinococcus granulosus recombinant antigens for serodiagnosis of unilocular hydatid disease (UHD) and postsurgical follow-up of patients treated for UHD. *Clin Vaccine Immunol* 2008; **15**: 147-153 [PMID: 17989342 DOI: 10.1128/CVI.00363-07]

73 **Gonlugur U**, Ozcelik S, Gonlugur TE, Celiksoz A. The role of Casoni's skin test and indirect haemagglutination test in the diagnosis of hydatid disease. *Parasitol Res* 2005; **97**: 395-398 [PMID: 16151737 DOI: 10.1007/s00436-005-1473-9]

74 **Sunita T**, Dubey ML, Khurana S, Malla N. Specific antibody detection in serum, urine and saliva samples for the diagnosis of cystic echinococcosis. *Acta Trop* 2007; **101**: 187-191 [PMID: 17335765 DOI: 10.1016/j.actatropica.2006.07.014]

75 **Ortona E**, Riganò R, Margutti P, Notargiacomo S, Ioppolo S, Vaccari S, Barca S, Buttari B, Profumo E, Teggi A, Siracusano A. Native and recombinant antigens in the immunodiagnosis of human cystic echinococcosis. *Parasite Immunol* 2000; **22**: 553-559 [PMID: 11116435 DOI: 10.1046/j.1365-3024.2000.00336.x]

76 **Rafiei A**, Craig PS. The immunodiagnostic potential of protoscolex antigens in human cystic echinococcosis and the possible influence of parasite strain. *Ann Trop Med Parasitol* 2002; **96**: 383-389 [PMID: 12171619 DOI: 10.1179/000349802125001195]

77 **Lorenzo C**, Ferreira HB, Monteiro KM, Rosenzvit M, Kamenetzky L, García HH, Vasquez Y, Naquira C, Sánchez E, Lorca M, Contreras M, Last JA, González-Sapienza GG. Comparative analysis of the diagnostic performance of six major Echinococcus granulosus antigens assessed in a double-blind, randomized multicenter study. *J Clin Microbiol* 2005; **43**: 2764-2770 [PMID: 15956395 DOI: 10.1128/JCM.43.6.2764-2770.2005]

78 **Rott MB**, Fernández V, Farias S, Ceni J, Ferreira HB, Haag KL, Zaha A. Comparative analysis of two different subunits of antigen B from Echinococcus granulosus: gene sequences, expression in Escherichia coli and serological evaluation. *Acta Trop* 2000; **75**: 331-340 [PMID: 10838217 DOI: 10.1016/S0001-706X(00)00069-3]

79 **Li J**, Zhang WB, Wilson M, Ito A, McManus DP. A novel recombinant antigen for immunodiagnosis of human cystic echinococcosis. *J Infect Dis* 2003; **188**: 1951-1960 [PMID: 14673776 DOI: 10.1086/379976]

80 **Parija SC**, Ravinder PT, Rao KS. Detection of hydatid antigen in urine by countercurrent immunoelectrophoresis. *J Clin Microbiol* 1997; **35**: 1571-1574 [PMID: 9163484]

**P-Reviewer:** Jose R, Ni Y **S-Editor:** Qiu S **L-Editor: E-Editor:**

**Table 1 Performance of hydatid cyst fluid in diagnosis of cystic echinococcosis in different serological assays**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Antigen | No of subjects | | | Test | Sensitivity (%) | Specificity (%) | Cross reactions | Yr | Ref. | |
|  |  |  |
|  | CE patients | Other disease | Healthy control |  |  |  |  |  |  | |
| SHCF | 78 | 24 | 15 | IgG ELISA | 72.4 |  | NR | 2001 | [71] | |
| BHCF | 129 | 65 | 203 | IgG ELISA | 77.6 | 96.6 | Cysts, Toxoc. | 2003 | [44] | |
| CHCF | 26 | 35 | 10 | dipstick assay | 100 | 91.4 | Cysts, AE, Trichinosis, Schist., Fascio, | 2004 | [6] |
| CHCF | 26 | 35 | 10 | EITB | 100 | 91.4 | Cysts, AE, trichinosis, Schist, Fascio. | 2004 | [6] | |
| CHCF | 26 | 30 | 10 | IgG ELISA | 96.2 | 100 | None | 2004 | [6] | |
| SHCF | 102 | 68 | 95 | IgG ELISA | 88.2 | 80.9 | AE, Cysts, Schist, Fascio, Taeniasis, Dirofilariasis | 2008 | [72] | |
| SHCF | 120 |  |  | Casoni's skin test | 88.2 | 80.9 | NR | 2005 | [73] | |
| SHCF | 120 |  |  | Casoni's skin test | 70 | 87 | NR | 2005 | [73] | |
| SHCF | 120 |  |  | Casoni's skin test | 62 | 85.00 | NR | 2005 | [73] | |
| SHCF | 120 |  |  | IHA | 56 | 84 | NR | 2005 | [73] | |
| SHCF | 25 | 15 | 25 | ELISA on Serum | 72 | 76 | Cysts, Ascaris, Ambs liver abscess | 2007 | [74] | |
| SHCF | 25 | 15 | 25 | ELISA on urine | 84 | 76 | Cysts, Ascaris, Ambs liver abscess | 2007 | [74] | |
| SHCF | 25 | 15 | 25 | ELISA on Saliva | 56 | 76 | Cysts, Ascaris, Ambs liver abscess | 2007 | [74] | |
| SHCF | 40 | 40 | 70 | CCIEP | 97.5 | 58.1 | Fascio, Toxoc, Taenia,  Malignancies | 2007 | [10] | |
| SHFF | 204 | 53 | 90 | IEP | 31 | 100 | None | 2000 | [75] | |
| SHFF | 204 | 53 | 90 | IHA | 54 | 100 | None | 2000 | [75] | |
| SHFF | 204 | 53 | 90 | IB | 80 | 96 | Cysts, Serous cysts | 2000 | [75] | |
|  | | | | | | | | | | |
| SHCF | 35 | 12 | 25 | Dot-ELISA | 100 | 89.1 | Ascaris, Taenia.,  Strogyl | 2010 | [1] | |
| SHCF | 35 | 12 | 25 | CCIEP | 80 | 62 | Ascaris, Strogyl.,  Toxop | 2010 | [1] | |
| SHCF | 59 | 60 | 39 | IgG ELISA | 91.5 | 96 | Clonorchiasis | 2013 | [76] | |
| hHCF | 50 | 15 | 20 | IB | 83 | 98 | None | 2014 | [28] | |
| hHCF | 50 | 15 | 20 | IgG IB | 83 | 98 | None | 2014 | [28] | |
| SHCF | 50 | 40 | 20 | IgG ELISA | 92 | 85 | Ascaris, Ambs,  Malignancy, Toxop | 2014 | [67] | |
| SHCF | 50 | 40 | 20 | IgM ELISA | 70 | 93.33 | Ascaris, Ambs,  Malignancy, Toxop. | 2014 | [67] | |
| SHCF | 50 | 40 | 20 | IgE ELISA | 86 | 96.66 | Ascaris, Ambs,  Malignancy, Toxop. | 2014 | [67] | |
| SHCF | 50 | 40 | 20 | IgG1 ELISA | 82 | 98.33 | Ascaris, Ambs, Malignancy, Toxop. | 2014 | [67] | |
| SHCF | 50 | 40 | 20 | IgG2 ELISA | 74 | 95 | Ascaris, Ambs,  Malignancy, Toxop. | 2014 | [67] | |
| SHCF | 50 | 40 | 20 | IgG3 ELISA | 52 | 36 | Ascaris, Ambs, Malignancy, Toxop. | 2014 | [67] | |
| SHCF | 50 | 40 | 20 | IgG4 ELISA | 86 | 28 | Ascaris, Ambs,  Malignancy, Toxop. | 2014 | [67] | |
| PsxAg | 113 | 112 | 121 | DIGFA | 87.6 | 90.90% | Hd, Cysts,  HCC, HH | 2015 | [48] | |
| CPsx extract | 147 | 88 | 60 | IgG ELISA | 90 | 57 | AE, Trypanosomiasis | 2002 | [76] | |
| Emwl Ag | 50 | 154 |  | WB IgG | 98 |  | NCC | 2000 | [14] | |
| Emwl Ag | 50 | 154 |  | IHA>80 | 94.3 |  | NR | 2000 | [14] | |
| Emwl Ag | 50 | 154 |  | IHA>320 | 80 |  | NR | 2000 | [14] | |
| Emwl Ag | 50 | 154 |  | IgG ELISA | 79.4 |  | NR | 2000 | [14] | |

EITB: Enzyme linked immunoelectrotransfer blot; IHA: Immune hemagglutination assay; CHCF: Camel hydatid cyst fluid; SHCF: Sheep hydatid cyst fluid; HHCF: Human hydatid cyst fluid; SHFF: Sheep Hydatid fluid fraction, Hd.: Hepatic distomiasis, Emwl Ag: Whole larval antigen from Echinococcus multilucolaris; CPsx extract: Crude protoescolex extract; Psx Ag: Protoscoleces antigen; BHCF: Bovine hydatid cyst fluid; Ascaris: Ascariasis; Toxop: Toxoplasmosis; Fascio: Fascioliasis; Cysts: Cysticercosis; Ambs: Amebiasis; Toxoc: Toxocariasis; Schist: Schistosomiasis; AE: Alveolar echinococcosis; NR: Not reported.

**Table 2 Performances of antigen 5 for immunodiagnosis of cystic echinococcosis in different serological assays**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **No of subjects** | | | **Test** | **Sensitivity**  **(%)** | **Specificity**  **(%)** | **Cross reaction** | **Yr** | **Ref.** |
|  | **CE patient** | **Other disease** | **Healthy control** |  |  |  |  |  |  |
| Ag 5 | 39 | 51 | 29 | IgG ELISA | 54 | 89 | AE | 2000 | [9] |
| Ag5 | 58 | 36 | 40 | IgG ELISA | 100 | 70.17 | Leish, Toxop, Fascio | 2006 | [39] |
| Ag5 | 58 | 36 | 40 | IgG1 ELISA | 100 | 70.17 | Leish, Toxop, Fascio | 2006 | [38] |
| Ag5 | 58 | 36 | 40 | IgG4 ELISA | 75.8 | 93.02 | Toxop, Fascio | 2006 | [38] |
| Ag5 | 58 | 36 | 40 | IgE ELISA | 70.1 | 100 | None | 2006 | [38] |
| rAg5 | 34 | 36 | 18 | IgG ELISA | 65 | 89 | AE, Cysts | 2005 | [77] |
| rAg5-38s | 34 | 36 | 18 | IgG ELISA | 21 | 97 | AE | 2005 | [77] |

Leish: Leishmaniasis; Toxop: Toxoplasmosis; Fascio: Fascioliasis; Cysts: Cysticercosis; AE: Alveolar echinococcosis.

**Table 3** **Performances of antigen B in diagnosis of cystic echinococcosis**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Antigen** | **No of subjects** | | | | | **Test** | **Sensitivity (%)** | **Specificity (%)** | **Cross reactions** | **Yr** | **Ref.** |
|  | CE  patients | | | Other disease | Healthy control |  |  |  |  |  |  |
| nAg B | 204 | | | 21 | 90 | IB | 66 | 100 | None | 2000 | [75] |
| nAg B | 59 | | | 55 | 15 | IgG ELISA | 80 | 77 | AE,NCC | 2005 | [77] |
| nAg B | 90 | | | 86 | 27 | IgG ELISA | 77 | 85 | AE,RA | 2000 | [9] |
| nAg B | 204 | | | 21 | 90 | IgG ELISA | 74 | 100 | None | 2000 | [75] |
| nAg B | 31 | | | 87 | 29 | IgG ELISA | 77.41 | 81.9 | AE, Ev, Schist, Toxoc. | 2000 | [78] |
| nAg B | 78 | | | 24 | 15 | IgG ELISA | 93.5 | 89.7 | Distomatosis, Schist. | 2001 | [71] |
| nAg B | 129 | | | 65 | 203 | IgG ELISA | 60.3 | 92.6 | Cysts,Toxoc. | 2003 | [44] |
| nAg B | 22 | | | 12 | 4 | WB | 77 | 100 | Toxoc, Other cestodes | 2010 | [30] |
| nAg B | 40 | | | 40 | 70 | IgG ELISA | 92.5 | 97.3 | Fascio | 2007 | [10] |
| nAg B | 40 | | | 40 | 70 | CCIEP | 97.5 | 58.2 | Fascio, Toxoc, Taenia., Malignancy | 2007 | *[10]* |
| nAg B | 204 | | | 53 | 90 | IB | 66 | 100 | None | 2000 | [75] |
| nAg B | 204 | | | 53 | 90 | IgG ELISA | 74 | 100 | None | 2000 | [75] |
| nAg B | 35 | | | 29 | 25 | IgG ELISA | 94.2 | 81.6 | NR | 2009 | [16] |
| nAg B | | 55 | | 72 | 50 | IgG ELISA | 96.4 | 97.2 | None | 2014 | [68] |
| nAg B | | 113 | | 112 | 121 | DIGFA | 92.9 | 81 | HD, Cysts, HCC, HH | 2015 | [48] |
| Goat liver Ag B | | 47 | | 30 | 40 | IgG ELISA | 91.4 | 92.8 | NR | 2011 | [49] |
| Human liver Ag B | | 47 | | 30 | 40 | IgG ELISA | 97.8 | 97.1 | NR | 2011 | [49] |
| Bovine lung Ag B | | 47 | | 30 | 40 | IgG ELISA | 78.7 | 85.7 | NR | 2011 | [49] |
| Sheep lung Ag B | | 47 | | 30 | 40 | IgG ELISA | 93.6 | 88.5 | NR | 2011 | [49] |
| Camel lung Ag B | | 47 | | 30 | 40 | IgG ELISA | 93.6 | 90 | NR | 2011 | [49] |
| Sheep liver Ag B | | 47 | | 30 | 40 | IgG ELISA | 95.7 | 92.8 | NR | 201 | [49] |
| rAg B | | 204 | 21 | | 90 | IB | 72 | 100 | None | 2000 | [75] |
| rAgB | | 113 | 112 | | 121 | DIGFA | 77.9 | 98.3 | None | 2015 | [48] |
| rAgB8/1 | | 31 | | 87 | 29 | IgG ELISA | 54.84 | 80.17 | AE, Schist, Toxoc. | 2000 | [78] |
|  | |  | |  |  |  |  |  |  |  |  |
| rAgB8/1 | | 129 | 65 | | 203 | IgG4 ELISA | 91.4 | 91.7 | Cysts | 2003 | [44] |
| rAgB8/1 | | 59 | 55 | | 15 | IgG ELISA | 68 | 88 | AE, NCC | 2005 | [80] |
| rAgB8/2 | | 31 | 87 | | 29 | IgG ELISA | 83.87 | 98.28 | Schist, Toxoc. | 2000 | [81] |
| rAgB8/2 | | 129 | 65 | | 203 | IgG ELISA | 93.1 | 99.5 | Cysts, Toxoc. | 2003 | [45] |
| rAgB8/2 | | 129 | 65 | | 203 | IgG4 ELISA | 69 | 87.5 | Cysts. | 2003 | [45] |
| rAgB8/2 | | 59 | 55 | | 15 | IgG ELISA | 45 | 86 | AE, NCC | 2005 | [77] |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| rAgB8/1 | | 129 | 65 | 203 | IgG4 ELISA | 91.4 | 91.7 | Cysts | 2003 | [44] |
| rAgB8/1 | | 59 | 55 | 15 | IgG ELISA | 68 | 88 | AE, NCC | 2005 | [77] |
| rAgB8/2 | | 31 | 87 | 29 | IgG ELISA | 83.87 | 98.28 | Schist, Toxoc. | 2000 | [78] |
| rAgB8/2 | | 129 | 65 | 203 | IgG ELISA | 93.1 | 99.5 | Cysts, Toxoc. | 2003 | [44] |
| rAgB8/2 | | 129 | 65 | 203 | IgG4 ELISA | 69 | 87.5 | Cysts. | 2003 | [44] |
| rAgB8/2 | | 59 | 55 | 15 | IgG ELISA | 45 | 86 | AE, NCC | 2005 | [77] |
| B1t | | 102 | 68 | 95 | IgG ELISA | 83.3 | 87.5 | AE, Schist, Cysts, Fascio, | 2008 | [9] |
| B2t | | 102 | 68 | 95 | IgG ELISA | 91.2 | 93 | Cysts, Schist, Fascio. | 2008 | [9] |
| 2B2t | | 186 | 174 | 110 | IgG ELISA | 87.6 | 99.1 | AE, NCC, Hepatitis | 2012 | [9] |
| rEgAFFPt | | 129 | 65 | 203 | IgG ELISA | 58.6 | 95.6 | Cysts, Toxoc. | 2003 | [44] |
| rEgCaBP2 | 129 | | 65 | 203 | IgG ELISA | 84.5 | 96.6 | Cysts, Toxoc. | 2003 | [44] |
| rEgcMDH | 129 | | 65 | 203 | IgG ELISA | 89.7 | 95.1 | Cysts. | 2003 | [44] |
| rEgAFFPf | 129 | | 65 | 203 | IgG ELISA | 69 | 89.7 | Cysts, Toxoc. | 2003 | [44] |
| rEpC1-GST | 324 | | 502 | 70 | IgG IB | 92.2 | 95.6 | AE, NCC, Schist,  Liver cancer | 2003 | [79] |
| rTPxEg | 100 | | 218 | 20 | IgG IB | 39 | 69.3 | AE, NCC | 2004 | [78] |
| rEgG5 | 23 | | 138 | 20 | IgG IB | 61 | 70 | AE, Cysts. | 2004 | [79] |
| E14t | 102 | | 68 | 95 | IgG ELISA | 35.3 | 91.7 | Schist | 2008 | [9] |
| C317 | 102 | | 68 | 95 | IgG ELISA | 58.8 | 80.9 | AE, Cysts, Taeniasis, Schist, | 2008 | [9] |
| p65 | 90 | | 86 | 27 | IgG ELISA | 44 | 96 | AE, Schist, Toxoc. | 2000 | [9] |
| p175 | 90 | | 86 | 27 | IgG ELISA | 49 | 94 | AE, Schist, Toxoc. | 2000 | [9] |
| p176 | 90 | | 86 | 27 | IgG ELISA | 80 | 93 | AE, Schist, Toxoc,  Syph, Chagas | 2000 | [9] |
| p177 | 90 | | 86 | 27 | IgG ELISA | 38 | 92 | AE, Toxoc, Syph,  Chagas | 2000 | [9] |
| pGu4 | 90 | | 86 | 27 | IgG ELISA | 18 | 98 | AE | 2000 | [9] |

Leish: Leishmaniasis; Toxop: Toxoplasmosis; Fascio: Fascioliasis; Cysts: Cysticercosis; AE: Alveolar echinococcosis; Ascaris: Ascariasis; Syph: Syphilis; Ambs: Amebiasis; Toxoc: Toxocariasis; Schist: Schistosomiasis; NCC: Neurocysticercosis; AE: Alveolar echinococcosis; NR: Not reported.

**Table 4** **Performances of antigen detection assays in immunodiagnosis of cystic echinococcosis**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Antigen** | **No of subjects** | | | **Test** | **Sensitivity (%)** | **Specificity (%)** | **Cross reaction (%)** | **Yr** | **Ref.** |
|  | **CE patient** | **Other disease** | **Healthy control** |  |  |  |  |  |  |
| Urinary antigen | 40 | 24 | 25 | Co-A | 50 | 89.09 | 12.5 | 2000 | [62] |
| Serum antigen | 40 | 24 | 25 | Co-A | 73.08 | 94.23 | 12.5 | 2000 | [62] |
| Serum antigen | 35 | 29 | 25 | IgG ELISA | 25.7 | 98 | VL | 2009 | [16] |
| Serum antigen | 141 | 25 | 25 | LAT | 72 | 98 | 4 | 2003 | [7] |
| Serum antigen | 40 | 24 | 25 | CIEP | 45 | 100 | None | 1997 | [80] |
| Urinary antigen (ucon.) | 40 | 24 | 25 | CIEP | 22.5 | 95.91 | 8.33 | 1997 | [80] |
| Urinary antigen (con.) | 40 | 24 | 25 | CIEP | 47.5 | 95.91 | None | 1997 | [80] |

EITB: Enzyme linked immunoelectrotransfer blot; IHA: Immune hemagglutination assay; CHCF: Camel hydatid cyst fluid; SHCF: Sheep hydatid cyst fluid; HHCF: Human hydatid cyst fluid; SHFF: Sheep Hydatid fluid fraction, Hd.: Hepatic distomiasis, Emwl Ag: Whole larval antigen from Echinococcus multilucolaris; CPsx extract: Crude protoescolex extract; Psx Ag: Protoscoleces antigen; BHCF: Bovine hydatid cyst fluid; Ascaris: Ascariasis; Toxop: Toxoplasmosis; Fascio: Fascioliasis; Cysts: Cysticercosis; Ambs: Amebiasis; Toxoc: Toxocariasis; Schist: Schistosomiasis; AE: Alveolar echinococcosis; NR: Not reported; VL: Visceral leishmaniasis; ucon: Unconcentrated; con: Concentrated.